World's Best Scientists 2026 revealed!

D-Index & Metrics

Medicine

D-Index
72
Citations
21762
World Ranking
19800
National Ranking
9861

Overview

Morton Coleman is affiliated with Cornell University in the United States and has contributed extensively to the field of medicine, particularly focusing on pathology and forensic medicine, genetics, oncology, molecular biology, and hematology. Their research work consists of 86 publications primarily within these areas.

The scientist's research topics mainly cover lymphoma diagnosis and treatment, chronic lymphocytic leukemia research, viral-associated cancers and disorders, multiple myeloma research and treatments, gastrointestinal tumor research and treatment, colorectal cancer treatments and studies, and lung cancer treatments and mutations.

Recent papers authored or co-authored by Morton Coleman include:

  • Phase II study of acalabrutinib in ibrutinib-intolerant patients with relapsed/refractory chronic lymphocytic leukemia, 2021, Haematologica
  • Durable ibrutinib responses in relapsed/refractory marginal zone lymphoma: long-term follow-up and biomarker analysis, 2020, Blood Advances
  • Phase 2 study of parsaclisib (INCB050465), a highly selective, next-generation PI3Kδ inhibitor, in relapsed or refractory diffuse large B-cell lymphoma (CITADEL-202), 2020, Leukemia & lymphoma/Leukemia and lymphoma
  • Involved-site radiotherapy for Helicobacter pylori-independent gastric MALT lymphoma: 26 years of experience with 178 patients, 2021, Blood Advances
  • A phase 2, multicentre, open-label trial (ACE-LY-003) of acalabrutinib in patients with relapsed or refractory marginal zone lymphoma, 2022, British Journal of Haematology

Morton Coleman's frequent co-authors include Abdulraheem Yacoub, Frederick Lansigan, Jason M. Melear, Mecide Gharibo, and David Andorsky. These collaborations have contributed to a number of studies, enhancing the breadth of research in hematology and oncology.

Frequent publication venues where Morton Coleman's work appears include:

  • Blood
  • Hematology Transfusion and Cell Therapy
  • Hematological Oncology
  • Blood Advances
  • Journal of Clinical Oncology

The primary fields of study for Morton Coleman are medicine with a strong focus on subfields such as pathology and forensic medicine, genetics, oncology, molecular biology, and hematology. The main topics addressed throughout their work encompass a wide range of cancer research areas, with particular focus on lymphomas and chronic lymphocytic leukemia.

Best Publications

  • Targeting BTK with Ibrutinib in Relapsed Chronic Lymphocytic Leukemia

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Ian W. Flinn

  • Three-year follow-up of treatment-naïve and previously treated patients with CLL and SLL receiving single-agent ibrutinib.

    John C. Byrd;Richard R. Furman;Steven E. Coutre;Jan A. Burger

  • Ibrutinib as initial therapy for elderly patients with chronic lymphocytic leukaemia or small lymphocytic lymphoma: an open-label, multicentre, phase 1b/2 trial

    Susan O'Brien;Richard R Furman;Steven E Coutre;Jeff P Sharman

  • A clinical study of the lupus anticoagulant

    Michael A. Schleider;Ralph L. Nachman;Eric A. Jaffe;Morton Coleman

  • PET Predicts Prognosis After 1 Cycle of Chemotherapy in Aggressive Lymphoma and Hodgkin’s Disease

    Lale Kostakoglu;Morton Coleman;John P. Leonard;Ichiei Kuji

  • Outcome of Deferred Initial Therapy in Mantle-Cell Lymphoma

    Peter Martin;Amy Chadburn;Paul Christos;Karen Weil

  • Bortezomib Plus CHOP-Rituximab for Previously Untreated Diffuse Large B-Cell Lymphoma and Mantle Cell Lymphoma

    Jia Ruan;Peter Martin;Richard R. Furman;Shing M. Lee

  • Persistent and relapsing babesiosis in immunocompromised patients.

    Peter J. Krause;Benjamin E. Gewurz;Benjamin E. Gewurz;David Hill;Francisco M. Marty

  • Ibrutinib Resistance in Chronic Lymphocytic Leukemia

    Richard R. Furman;Shuhua Cheng;Pin Lu;Menu Setty

  • Epratuzumab, a humanized anti-CD22 antibody, in aggressive non-Hodgkin's lymphoma: phase I/II clinical trial results.

    John P. Leonard;Morton Coleman;Jamie C. Ketas;Amy Chadburn

  • Tositumomab and Iodine-131 Tositumomab Produces Durable Complete Remissions in a Subset of Heavily Pretreated Patients With Low-Grade and Transformed Non-Hodgkin’s Lymphomas

    Richard I. Fisher;Mark S. Kaminski;Richard L. Wahl;Susan J. Knox

  • Evidence of a new chimeric bcr/c-abl mRNA in patients with chronic myelocytic leukemia and the Philadelphia chromosome.

    K Stam;N Heisterkamp;G Grosveld;A de Klein

  • Phase I/II Trial of Epratuzumab (Humanized Anti-CD22 Antibody) in Indolent Non-Hodgkin’s Lymphoma

    John P. Leonard;Morton Coleman;Jamie C. Ketas;Amy Chadburn

  • The predictive role of interim positron emission tomography for Hodgkin lymphoma treatment outcome is confirmed using the interpretation criteria of the Deauville five-point scale.

    Andrea Gallamini;Sally F. Barrington;Alberto Biggi;Stephane Chauvie

  • Comparison of fluorine-18 fluorodeoxyglucose positron emission tomography and Ga-67 scintigraphy in evaluation of lymphoma.

    Lale Kostakoglu;John P. Leonard;John P. Leonard;Ichiei Kuji;Morton Coleman;Morton Coleman

  • Targeting Bruton tyrosine kinase with ibrutinib in relapsed/refractory marginal zone lymphoma.

    Ariela Noy;Ariela Noy;Sven de Vos;Catherine Thieblemont;Peter Martin

  • Combination chemotherapy of advanced diffuse histiocytic lymphoma with the six-drug COP-BLAM regimen.

    Jeffrey Laurence;Morton Coleman;Steven L. Allen;Richard T. Silver

  • BiRD (Biaxin®[clarithromycin]/Revlimid®[lenalidomide]/dexamethasone) combination therapy results in high complete- and overall-response rates in treatment-naive symptomatic multiple myeloma

    Ruben Niesvizky;David S. Jayabalan;Paul J. Christos;Jessica R. Furst

  • Lenalidomide plus Rituximab as Initial Treatment for Mantle-Cell Lymphoma.

    Jia Ruan;Peter Martin;Bijal Shah;Stephen J. Schuster

  • Combination Antibody Therapy With Epratuzumab and Rituximab in Relapsed or Refractory Non-Hodgkin's Lymphoma

    John P. Leonard;Morton Coleman;Jamie Ketas;Michelle Ashe

Frequent Co-Authors

John P. Leonard
John P. Leonard Cornell University
Richard R. Furman
Richard R. Furman NewYork–Presbyterian Hospital
Richard T. Silver
Richard T. Silver Cornell University
Selina Chen-Kiang
Selina Chen-Kiang Cornell University
Paul J. Christos
Paul J. Christos Cornell University
Stanley J. Goldsmith
Stanley J. Goldsmith Cornell University
Anne J. Novak
Anne J. Novak Mayo Clinic
David M. Goldenberg
David M. Goldenberg Immunomedics (United States)

If you think any of the details on this page are incorrect, let us know.

Report an issue

We appreciate your kind effort to assist us to improve this page, it would be helpful providing us with as much detail as possible in the text box below:

Related Online Degrees & Career Pathways

Interested in broadening your options within healthcare? There are several affordable and flexible online degrees that can help you enter or advance in key medical fields. If you’re aiming for advanced clinical practice, exploring cheap dnp online programs can be a cost-effective way to earn a Doctor of Nursing Practice and boost your career prospects.

For those drawn to pharmaceuticals, accredited online pathways such as pharmacy school online accredited programs make it possible to study pharmacy without relocating—offering a practical route into this high-demand sector.

Not all healthcare roles are patient-facing. If you have an interest in informatics or management, a health information management bachelor degree online can open doors to essential administrative and data-driven positions in hospitals and clinics.

Meanwhile, certification in fields like medical coding certification is ideal for those seeking a specialized role in medical billing or coding, with flexible learning options to fit any schedule.

Best Scientists Citing Morton Coleman

Trending Scientists

Recently Published Articles